neurotrophic factor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-01. Anything still debated is marked as such rather than presented as settled.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
=== Living with TPN === Approximately 40,000 people use TPN at home in the United States, and because TPN requires 10–16 hours to be administered, daily life can be affected. Although daily lifestyle can be changed, most patients agree that these changes are better than staying at the hospital. Many different types of pumps exist to limit the time the patient is "hooked up". Usually a backpack pump is used, allowing for mobility. The time required to be connected to the IV is dependent on the situation of each patient; some require once a day, or five days a week. It is important for patients to avoid as much TPN-related change as possible in their lifestyles. This allows for the best possible mental health situation; constantly being held down can lead to resentment and depression. Physical activity is also highly encouraged, but patients must avoid contact sports (equipment damage) and swimming (infection). Many teens find it difficult to live with TPN due to issues regarding body image and not being able to participate in activities and events.
the Kremlin walls Zemlyanoy Gorod (Earthwork Town) the Kamer-Kollezhsky Rampart the Garden Ring the small railway ring The Moscow Ring Road (MKAD) has been Moscow's boundary since 1960. Similarly circular are the main Moscow subway line, the Ring Line, and the so-called Third Automobile Ring (which was completed in 2005). Thus, radial and circular planning continues to define Moscow's development. However, contemporary Moscow has also absorbed a number of areas outside the MKAD—such as Solntsevo, Butovo, and the town of Zelenograd. Part of Moscow Oblast's territory was merged into Moscow on 1 July 2012; as a result, Moscow is no longer fully surrounded by Moscow Oblast, and the city now shares a border with Kaluga Oblast. In total, Moscow gained about 1,500 square kilometers (580 sq mi) and 230,000 inhabitants. Moscow's Mayor Sergey Sobyanin praised this expansion as helping Moscow and the neighboring region, a "mega-city" of 20 million people, to develop "harmonically". Each administrative okrug and district has its own coat of arms and flag, as well as an individual leader. In addition to the districts, there are Territorial Units with Special Status. These units usually include areas with small or no permanent populations. Examples include the All-Russia Exhibition Centre, the Botanical Garden, large parks, and industrial zones. In recent years, some territories have been merged with other districts. Moscow has no ethnic-specific areas, such as the Chinatowns in certain North American and East Asian cities.
Relatively strong reducing acids can have antinutrient effects by binding to dietary minerals such as iron and zinc in the gastrointestinal tract and preventing them from being absorbed. Examples are oxalic acid, tannins and phytic acid, which are high in plant-based diets. Calcium and iron deficiencies are not uncommon in diets in developing countries where less meat is eaten and there is high consumption of phytic acid from beans and unleavened whole grain bread. However, germination, soaking, or microbial fermentation are all household strategies that reduce the phytate and polyphenol content of unrefined cereal. Increases in Fe, Zn and Ca absorption have been reported in adults fed dephytinized cereals compared with cereals containing their native phytate.
Within the skin, melanocytes are present in the basal layer of the epidermis; from these, melanocytes originate dendrites that reach keratinocytes. Melanosomes, along with the melanin they contain, are transferred from melanocytes to keratinocytes when keratinocytes are low in the epidermis. Keratinocytes carry the melanosomes with them as they move toward the surface. Keratinocytes contribute to skin pigmentation by holding the melanin originating in melanocytes and inducing melanogenesis through chemical signals directed at melanocytes. The transfer of melanosomes to keratinocytes is a necessary condition for the visible pigmentation of the skin. Blocking this transfer is a mechanism of action of some skin whitening agents. The protease-activated receptor 2 (PAR2) is a transmembrane and G-protein coupled receptor expressed in keratinocytes and involved in melanocyte transfer. Antagonists of PAR2 inhibit the transfer of melanosomes and have skin whitening effects, while agonists of PAR2 have the opposite effect.
Sources: en.wikipedia.org
== See also == Atomic absorption spectrophotometry Atomic emission spectroscopy Inductively coupled plasma atomic emission spectroscopy Inductively coupled plasma mass spectrometry LBOZ Microspectrophotometry Slope spectroscopy Spectroradiometry
According to this equation, maximum resolution is reached when the electrophoretic and electroosmotic mobilities are similar in magnitude and opposite in sign. In addition, it can be seen that high resolution requires lower velocity and, correspondingly, increased analysis time. Besides diffusion and Joule heating (discussed above), factors that may decrease the resolution in capillary electrophoresis from the theoretical limits in the above equation include, but are not limited to, the finite widths of the injection plug and detection window; interactions between the analyte and the capillary wall; instrumental non-idealities such as a slight difference in height of the fluid reservoirs leading to siphoning; irregularities in the electric field due to, e.g., imperfectly cut capillary ends; depletion of buffering capacity in the reservoirs; and electrodispersion (when an analyte has higher conductivity than the background electrolyte). Identifying and minimizing the numerous sources of band broadening is key to successful method development in capillary electrophoresis, with the objective of approaching as close as possible to the ideal of diffusion-limited resolution.
The Academy of Television Arts & Sciences acknowledged season 3 at their Primetime Emmy Award ceremonies seven times. At the 78th Primetime Emmy Awards, the season got one nomination; Zendaya's turn in episode eight "In God We Trust" was nominated for her third Outstanding Lead Actress in a Drama Series. At the 78th Primetime Creative Arts Emmy Awards, the season was nominated for Outstanding Guest Actor in a Drama Series (Domingo for the series finale), Outstanding Cinematography for a Series (One Hour) (Marcell Rév for the series finale), Outstanding Picture Editing for a Drama Series (Nikola Boyanov, Aleshka Ferrero, Aaron I. Butler, Julio C. Perez IV, and Kristin Valentine for "In God We Trust"), Outstanding Production Design for a Narrative Contemporary Program (One Hour or More) (François Audouy, A. Todd Holland, and Anthony Carlino for episode five "This Little Piggy"), Outstanding Hairstyling (Kimberly Kimble, Kendra Garvey, Kase Glenn, Marquita Lynch, and Stacy Schneiderman for episode three "The Ballad of Paladin"), and Outstanding Makeup (Non-Prosthetic) (Doniella Davy, Mara Rouse, Tara Lang Shah, and Leah Rial Sappington for episode four "Kitty Likes to Dance").
==== siRNA delivery ==== Short interfering RNA (siRNA) is a powerful new tool that can interfere with and silence the expression of specific disease gene. To improve cellular uptake of siRNA, CPP strategies have been applied to facilitate the delivery of siRNA into cells through either covalent or non-covalent linkages. In one study, siRNA is covalently linked to transportation and penetration by disulfide-linkage at 5'-end of the sense strands of siRNA to target luciferase or eGFP mRNA reporters. In another study, TAT-siRNA conjugate through a stable thiomaleimide linkage at 3'-end of siRNA was delivered into HeLa cells for eGFP gene silencing. However, non-covalent strategies appear to be better for siRNA delivery with a more significant biological response. In one study, MPG/siRNA complexes formed through stable non-covalent strategy showed successful introduction of siRNA into cultured cells and induced robust regulation of target mRNA. Furthermore, MPG/siRNA complexes have also been applied for delivery of siRNA in vivo into mouse blastocytes for gene regulation. MPG forms stable complexes with siRNA with a low degradation rate and can be easily functionalized for specific targeting, which are major advantages compared with the covalent CPP technology.
== Research == Multiple studies have shown that LDN has promise as a treatment for chronic pain, some autoimmune disorders, and cancers. Studies on the efficacy of LDN for multiple sclerosis have been inconclusive. Clinical trials for its use as treatment of fibromyalgia were initiated in 2021. LDN is also being studied in long COVID. A 2018 therapeutic utilization review concluded that LDN may be an appropriate option for treatment of fibromyalgia and irritable bowel syndrome, but that "proper clinical trials are needed in order to establish evidence that could lead to correct indications, mode of administration, and other aspects necessary for effective clinical pharmacology of [low-dose naltrexone]." The UK's National Health Service echoed this sentiment in 2020. In a 2013 paper published in Arthritis & Rheumatology, authors Jarred Younger and Sean Mackey reported reduced circulating pro‑inflammatory cytokines and self‑reported pain in fibromyalgia patients using LDN. A 2018 review summarized mixed trial outcomes and emphasized methodological limitations. A 2023 systematic review published in the Australian Journal of General Practice found that preliminary research into the use of LDN as a treatment for fibromyalgia is promising. All clinical studies examined showed statistically significant improvements in pain and pain tolerance with mild side effects; however, sample sizes were small and the evidence is inconclusive.
Sources: en.wikipedia.org
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea, and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. A new wave of fentanyl analogues and associated deaths began in around 2014 in the US, and have continued to grow in prevalence; especially since 2016 these drugs have been responsible for hundreds of overdose deaths every week.
In November 2020, Hetero signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture more than 100 million doses of Sputnik V, the world’s first registered COVID-19 vaccine. Hetero continued its response to COVID-19 with the launch of Movfor (molnupiravir) in late 2021 and Nirmacom (a generic version of nirmatrelvir-ritonavir) in 2022. In December 2022, Nirmacom became the first generic adaptation of the COVID treatment to receive WHO prequalification, allowing Hetero to distribute it to 95 LMICs under a voluntary license administered through the Medicines Patent Pool. 2023- Present In 2023, Hetero celebrated 30 years of its journey from a small-time API producer to a global pharmaceutical manufacturing powerhouse. In 2024, Hetero entered a partnership with Gilead Sciences to expand availability of Lenacapavir, a long acting injectable HIV treatment, across 120 high-incidence countries in order to support the global HIV response. In 2025, Hetero opened a new commercial office in Warsaw, Poland, marking the company’s formal entry into the Eastern European pharmaceutical markets. In 2026, Hetero launched generic versions of semaglutide - the active ingredient in medicines for type 2 diabetes and obesity management- in emerging markets under the names Truglyx, Rolmodl, and Moto G.
Baritosis, a benign pneumoconiosis is associated with inhalation of dust containing barium sulfate or barium carbonate; the effects are reversible. Silver poisoning, like lithium poisoning, arises from misapplication of medications. A dramatic symptom of "argyria" is that the skin turns blue or bluish-grey. Thallium poisoning has been observed on several occasions, and it is well known that thallium compounds are highly toxic. Nonetheless, incidents of thallium poisoning are few. Tin poisoning from tin metal, its oxides, and its salts are "almost unknown"; on the other hand certain organotin compounds are almost as toxic as cyanide. Such organotin compounds were once widely used as anti-fouling agents.
Bacteria can use flagella in different ways to generate different kinds of movement. Many bacteria (such as E. coli) have two distinct modes of movement: forward movement (swimming) and tumbling. The tumbling allows them to reorient and makes their movement a three-dimensional random walk. Bacterial species differ in the number and arrangement of flagella on their surface; some have a single flagellum (monotrichous), a flagellum at each end (amphitrichous), clusters of flagella at the poles of the cell (lophotrichous), while others have flagella distributed over the entire surface of the cell (peritrichous). The flagella of a group of bacteria, the spirochaetes, are found between two membranes in the periplasmic space. They have a distinctive helical body that twists about as it moves. Two other types of bacterial motion are called twitching motility that relies on a structure called the type IV pilus, and gliding motility, that uses other mechanisms. In twitching motility, the rod-like pilus extends out from the cell, binds some substrate, and then retracts, pulling the cell forward. Motile bacteria are attracted or repelled by certain stimuli in behaviours called taxes: these include chemotaxis, phototaxis, energy taxis, and magnetotaxis. In one peculiar group, the myxobacteria, individual bacteria move together to form waves of cells that then differentiate to form fruiting bodies containing spores. The myxobacteria move only when on solid surfaces, unlike E. coli, which is motile in liquid or solid media.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.